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Kathryn B. Garber1,*Mosaic AKT1 Mutation Found in Proteus Syndrome
Proteus syndrome is an atypical genetic condition, in that
it has never been reported to recur in a family and it has
been observed in one twin of an identical pair. Even within
an affected individual, the overgrowth and tissue hyper-
plasia that are characteristic of the disorder are patchy.
These features suggested the hypothesis that Proteus
syndrome is caused by a somatic mutation that is lethal
when it is present throughout the body. Following this
idea, Lindhurst et al. compared exomes from affected and
unaffected tissues of individuals suffering from Proteus
syndrome in the hope of identifying causative somatic
mutations. In 26 of 29 individuals, the identical activating
mutation in the oncogene AKT1 was found in affected
tissues in proportions ranging from 1% to 50%. The
same mutation was not found in unaffected relatives, nor
in control samples. Supporting this mutation as the culprit
is the fact that mice expressing activating forms of Akt1
share features reminiscent of Proteus syndrome. Beyond
a better understanding of Proteus syndrome, these results
indicate that molecular diagnosis will require biopsy
samples of affected tissue, because a small minority of
peripheral-blood samples from patients with Proteus
syndrome were positive for the AKT1 mutation.
Lindhurst et al. (2011) NEJM. Published online July 27,
2011. 10.1056/NEJMoa1104017.
Genomes Get More Personal with Structural Variation
Now that many human genomes and exomes have been
sequenced, it has become fairly standard to compare
them and identify differences at the DNA sequence
level. At this point, millions of SNPs have been discov-
ered. Given that second-generation sequencing technol-
ogies generate very short reads of sequence, what has
been harder to find are sites of small to intermediate-
sized structural variation (SV). Li et al. recently used a
method of de novo whole-genome assembly from short
sequence reads to characterize a wider swath of SVs in
an Asian and an African genome. Of the more than
200,000 sites of SV they found, several thousand were
located within gene bodies, which could mean they
play a substantial role in human diversity. When they
considered these SVs in 106 individuals for whom
genome data are available via the 1000 Genomes Project,
they found an excess of SVs at low frequency, even rela-
tive to SNPs, and they use this to argue that SVs could1Department of Human Genetics, Emory University School of Medicine, Atlan
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genome unique.
Li et al. (2011) Nature Biotechnology 29, 723–730.
Progress towards Molecular Therapy for Duchenne
Muscular Dystrophy
In cell-culture and animalmodels, exon-skipping strategies
designed to ameliorate the downward spiral of muscle
damage in Duchenne muscular dystrophy (DMD) are
promising. Data on their safety and efficacy in affected
boys are just beginning to come available, including
a recent open-label dose-escalation study of the phosphor-
odiamidate morpholino oligomer AVI-4658, which is de-
signed to skip exon 51 of DMD. In contrast to an earlier
published trial, the drug in this case was administered
systemically, via weekly intravenous infusions, which
theoretically could allow it to get to both cardiac and skel-
etal muscle. Even with systemic administration, AVI-4658
proved to be well tolerated in their cohort of 19 affected
boys. Although the study did not last long enough to
look at clinical efficacy, AVI-4658 does restore some dystro-
phin expression in patients with DMD; muscle fibers
from six of eight boys in the two highest-dose cohorts
expressed more dystrophin posttreatment. This dystro-
phin appears to be functional, because it was associated
with concomitant increases in the expression of dystro-
phin-associated proteins, as well as with decreases in
inflammation. Although we are far from proving that
exon-skipping strategies are going to be an effective inter-
vention for patients with DMD, these results mean they at
least have the potential to do so and argue for additional
clinical trials of these strategies.
Cirak et al. (2011) Lancet 378, 595–605.
Sibling Recurrence Risks for Autism
When a family has a child with autism, one question they
often have is,Will this happen again? Previous epidemiolog-
ical studies have addressed this question, but there has
been some question of whether the risk estimates were
underestimated due to stoppage, which is the fact that
families are less likely to have more children after having
one with disabilities, or overestimated due to ascertain-
ment bias towards families with more than one affected
child. Ozonoff et al. recently published a study that was
designed to get around some of these issues, and they
found a sibling recurrence risk that is substantially higherta, GA 30322, USA
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than previous estimates. To avoid problems with stoppage,
the authors collected families with an autistic child who
already had a younger infant sibling. Then, to get around
the ascertainment bias issue, they followed the infant
siblings prospectively until they were at least three years
old, at which point the children were given a thorough
evaluation for autism. Among the more than 650 younger
siblings in the study, the recurrence risk was found to be
18.7%. Though even this risk in the overall group is higher
than previous estimates, it is further increased inmales and
in those with more than one affected older sibling.
Ozonoff et al. (2011) Pediatrics. Published online August 15,
2011. 10.1542/peds.2010-2825.
Large-Scale Recombination Maps Generated
for African American Populations
Recombination does not occur with equal frequency
across the genome; rather, there are hotspots at which it
is more likely to occur. Large-scale genetic maps can be
created that assess the likelihood that crossing over will
occur at each position across the genome, but they have
largely been produced with data from European-derived
populations for whom extensive genealogical data are
available—such as the Hutterite and Icelandic popula-
tions—and may not be representative of other popula-
tions. A lack of extensive genealogical data for many352 The American Journal of Human Genetics 89, 351–353, Septembpopulations makes it harder to generate recombination
maps for comparison, but this problem has recently been
remedied through assessment of ancestry switching in
SNP data from African Americans, a genetically admixed
population. In other words, when the SNP data from
an individual indicate that a run of European-derived
SNP alleles is adjacent to African-derived alleles, it is likely
that recombination has occurred between them. On
the level of 1–3 Mb, the recombination maps generated
through this approach correlate well with European-
derived recombination maps, such as the one produced
by deCODE for the Icelandic population. However, on
a finer scale, differences do exist. Wegmann et al. report
that significant interpopulation differences in recombina-
tion rate occur at sites of structural variation, including the
common inversion at chromosome 8p23.1. Hinch et al.,
on the other hand, found less than 2000 recombination
hotspots associated with West African, but not European,
ancestry. These ‘‘African-enriched’’ hotspots are largely
controlled by variation at PRDM9, and the authors are
able to link a sequence motif enriched in the hotspots
with the preferred binding site for the common West
African PRDM9 allele.
Hinch et al. (2011) Nature 476, 170–175.
Wegmann et al. Nature Genetics. Published online July 20,
2011. 10.1038/ng.894.This Month in Our Sister JournalsEnsuring a Job Well Done
A job worth doing is worth doing well, or so the saying
goes. Sometimes, it helps to know how well you’re doing
compared to others. That’s the rationale behind the devel-
opment of laboratory quality-assurance programs in which
blinded samples are used by accrediting agencies in order
to assess laboratory performance and to allow each lab to
improve their work. Unfortunately, when it comes to labo-
ratory testing for mitochondrial disease via measurements
of the activity of the respiratory chain complex, no such
programs exist. I certainly wouldn’t jump to the head of
the line to provide enough muscle biopsies for every lab
to test. Fibroblast cell lines from patients with mitochon-
drial disease would be a potential renewable source of
samples for this testing; however, the effects of mitochon-
drial defects on cell growth also make this difficult. Chen
et al. came up with the idea that mitochondria from
C. elegans could be used to compare measurements of
respiratory chain complex activity between testing labs.
Given that a range of mutant worms that have defects in
this complex is available, there is essentially an endless
supply of testing samples for labs to use. In their pilot
program, six testing labs participated and tested identicalC. elegans samples for respiratory chain complex activity,
using their own protocols. Although there was overall
concordance in detecting the general defects present in
the mutant strains, there was enough variability in the
assays and their interpretation to argue for further develop-
ment of this type of comparative testing for mitochondrial
defects.
Chen et al. (2011) Genetics in Medicine. Published online
May 30, 2011. 10.1097/GIM.0b013e31821afca5.
We’re All Inbred if You Look Hard Enough
I live in the South, so I’m quite familiar with the jokes
about cousins marrying each other. All joking aside,
inbreeding in humans is actually very common with
more than 10% of the world’s population estimated to
be a product of second-cousin or closer relationships. The
problem with inbreeding, genetically speaking, is that it
increases the likelihood that a child will have a rare reces-
sive genetic disease. Increasing evidence suggests that
inbreeding could also make a substantial contribution to
complex traits via homozygosity for deleteriousmutations.
To look for the effects of inbreeding, one must use the
inbreeding coefficient, F, which traditionally has beener 9, 2011
estimated with the use of pedigrees. Generally, families can
only be traced back a handful of generations, though,
meaning that these calculations of F are focused on recent
inbreeding and do not take into account the inbreeding
that results from distant common ancestors. The avail-
ability of large-scale SNP data in outbred populations
makes it possible to measure inbreeding in new ways.
Keller et al. compared various methods of calculating F
from SNP data and found that it is possible to identifyThe Americanevidence of both recent and more ancient inbreeding
and that themost powerful method is based on assessment
of runs of SNP allele homozygosity. Unfortunately, the
variance of F is low, meaning that very large sample sizes,
on the order of tens of thousands of samples, will be neces-
sary to detect the effects of inbreeding on complex traits in
outbred human populations.
Keller et al. (2011) Genetics, Published online July 29, 2011.
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